Blue-Chip

4 Popular Stocks under the lens for growth – ALL, WEB, CAN, BAP

October 11, 2018 | Team Kalkine
4 Popular Stocks under the lens for growth – ALL, WEB, CAN, BAP


 

Aristocrat Leisure Limited

Launching in various markets in October 2018: Aristocrat Leisure Limited’s (ASX: ALL) stock rose 2.6% on October 10, 2018 after the company gave 2018 G2E investor presentation. The company has highlighted in the presentation that the acquisition of Plarium and Big Fish had significantly increased the scale of the company’s Digital business. The company continues to invest in premium video hardware and the expanding portfolio of Gaming operations into low, mid and high denomination segments. Lightning Link & Dragon Link are dominating the top performing lease games list and the company plans to release Dollar Storm in 2019. For Outright sale, ALL is on track to go live in Washington market in October 2018 and has strategic partnership with Tulalip tribe, Aristocrat sponsor. The company is also on track to launch in Manitoba market by mid-October 2018. Meanwhile, Dr. Ian Blackburne will retire as the Chairman of the company on 21 February 2019 and will be succeeded by current Non-Executive Director, Mr. Neil Chatfield. On the other hand, ALL stock is trading at the price of level $27.93, has resistance at $32.9 and support at $26.77. ALL stock has fallen 12.95% in three months as on October 09, 2018  and is still trading at a high P/E. Based on the foregoing, we have a Wait and Watch view on the stock at the current price of 27.930.
 

Webjet Limited

Cautious on oil price: Webjet Limited’s (ASX: WEB) stock has risen 6.31% in three months as on October 09, 2018, after the company reported robust FY 18 with 54% rise in Total Transaction Value to $3 billion, 54% rise in revenue to $291 million, 71% increase in EBITDA to $87.4 million and 30% growth in Net profit after tax (NPAT) to $43.2 million. During FY18, the company experienced strong organic bookings growth with all regions growing significantly faster than their underlying markets. The company had delivered strong growth in Europe, and is now the #2 player in MEA, and the Americas and Asia both grew significantly during FY 18. TTV margins expanded largely due to increased size in all regions, as well as more sales from higher margin direct contracts. Moreover, for FY 19, WEB has reiterated the bookings’ growth targets for both the B2C and B2B businesses, and expects bookings growth rate of more than 3 times the underlying market for B2C and more than 5 times the underlying market for B2B. However, oil prices are recovering after a further decline in Iran’s exports. Major oil traders are projecting the Brent crude oil price to be above US$100 a barrel in the near future due to OPEC and its allies are struggling to fill the gap caused by U.S. sanctions on Iran’s oil exports. Meanwhile, WEB stock is also trading at a high P/E. The stock is trading at the price level of $14.27, has resistance at $17.58 and support at $13. Based on the foregoing, we maintain a wait and watch stance on the stock at the current price.
 

FY 18 Financial Performance (Source: Company Reports)
 

Cann Group Limited

Decent Outlook: Cann Group Ltd.’s (ASX: CAN) stock has fallen 9.84% in three months as on October 09, 2018 after the company reported 82.61% rise in net loss in FY 18. The stock is trading at the price of level $2.78, and has resistance at $3.21 and support at $2.66. However, by the end of FY 19, the company expects that the construction on the Phase 3 expansion facility will be well underway. The company also expects to maintain strong momentum, and is progressing with the development of a range of new dosage forms, suitable for patients in Australia and in overseas markets. CAN has already secured the export licence, and is working with the authorities to gain approval for the permits which will allow the company to start export sales. CAN plans to step up the engagement with the medical community to ensure medical professionals have the resources they require to make considered decisions on the suitability of medicinal cannabis treatment for their patients. Among the cannabis stocks listed on ASX, CAN has a decent footing and fundamentals. Based on the foregoing, we give a “Speculative Buy” recommendation on the stock at the current price of $ 2.780.
 

FY 18 Financial Performance (Source: Company Reports)
 

Bapcor Limited

Strong Performance in FY 18: Bapcor Ltd.’s (ASX: BAP) stock has risen 6.81% in three months as on October 09, 2018 after the company for FY 18 reported 22% and 47.8% rise in the statutory revenue and net profit after tax respectively compared to FY17. Pro-forma net profit after tax from continuing operations increased by 31.6% in FY 18 on the back of the impact of the acquisition of Hellaby’s automotive businesses and good profit growth across all of Bapcor’s automotive business segments. Further, for FY 19, BAP is projecting continued revenue and profit growth in FY19. The company expects EBITDA of approximately $170M that is at a reasonable level, leading to an increase in NPAT of between 9% and 14% above FY18 proforma NPAT. Meanwhile, BAP stock is trading at a P/E of 21.74x, and has resistance at $7.65 and support at $6.55. Based on the foregoing and the run-up so far, we give a “Hold” recommendation on the stock at the current price of  $ 7.300.
 


Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.